PARP1 and lung carcinoma: To investigate the potential of using PARP inhibitors to target the DDR pathway in lung cancer as a novel therapeutic approach, hATM KO isogenic cell lines were used to help elucidate the molecular mechanism associated with the synthetic lethality between hATM KO and PARPi treatment.